In human T2D skeletal muscle samples, Pak1 protein levels were reduced post‐transcriptionally, along with its effector ARPC1B (Actin‐Related Protein 2/3 Complex Subunit 1B) (Merz et al. 2022), a protein that is part of the ARP2/3 complex responsible for regulating the structure and dynamics of the actin cytoskeleton and crucial for GLUT4 translocation, suggesting that stabilizing Pak1 levels in skeletal muscle could improve glucose uptake and help manage insulin resistance in T2D patients. The gene discussed is SLC2A4; the disease is type 2 diabetes mellitus.